Himori N, Ishimori T, Taira N
Arch Int Pharmacodyn Ther. 1979 Nov;242(1):115-27.
Experiments were carried out on 7 conscious, renal hypertensive dogs with 7 beta-adrenoceptor blocking agents (atenolol, bunitrolol, bunolol, carteolol, nadolol, sotalol and timolol). Three main conclusions may be made from this study: (1) the stronger the beta-adrenoceptor blocking activity the stronger the antihypertensive action; (2) for the antihypertensive action, very strong beta-adrenoceptor blocking activity was needed; (3) d-carteolol, unlike dl-carteolol, had no antihypertensive effect. Thus, the beta-adrenoceptor blocking action per se is a prerequisite for the antihypertensive effect of the beta-adrenoceptor blocking agents.
对7只清醒的肾性高血压犬使用7种β-肾上腺素能受体阻滞剂(阿替洛尔、布尼洛尔、丁萘洛尔、卡替洛尔、纳多洛尔、索他洛尔和噻吗洛尔)进行了实验。从本研究中可得出三个主要结论:(1)β-肾上腺素能受体阻滞活性越强,降压作用越强;(2)对于降压作用,需要非常强的β-肾上腺素能受体阻滞活性;(3)与消旋卡替洛尔不同,右旋卡替洛尔没有降压作用。因此,β-肾上腺素能受体阻滞作用本身是β-肾上腺素能受体阻滞剂产生降压作用的前提条件。